Wedbush Reaffirms Outperform Rating for Lexicon Pharmaceuticals Inc. (LXRX)
Wedbush reissued their outperform rating on shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) in a report issued on Tuesday. Wedbush currently has a $33.00 target price on the biopharmaceutical company’s stock.
LXRX has been the topic of a number of other reports. Cowen and Company reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Friday, September 9th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 6th. Needham & Company LLC restated a buy rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, August 11th. Citigroup Inc. initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 2nd. They set a buy rating and a $21.00 price target for the company. Finally, Stifel Nicolaus raised their price target on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a buy rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of Hold and a consensus price target of $20.93.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 18.82 on Tuesday. The company’s market capitalization is $1.95 billion. Lexicon Pharmaceuticals has a 52 week low of $7.65 and a 52 week high of $19.62. The firm’s 50-day moving average price is $16.22 and its 200-day moving average price is $14.27.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.36 million. During the same period last year, the business earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 5186.8% compared to the same quarter last year. On average, equities analysts expect that Lexicon Pharmaceuticals will post ($1.54) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Paradigm Asset Management Co. LLC purchased a new position in Lexicon Pharmaceuticals during the second quarter worth about $115,000. First Mercantile Trust Co. boosted its position in Lexicon Pharmaceuticals by 9.2% in the second quarter. First Mercantile Trust Co. now owns 10,700 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 900 shares during the period. Alambic Investment Management L.P. purchased a new position in Lexicon Pharmaceuticals during the second quarter worth about $165,000. BlackRock Group LTD boosted its position in Lexicon Pharmaceuticals by 56.9% in the first quarter. BlackRock Group LTD now owns 14,217 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 5,158 shares during the period. Finally, A.R.T. Advisors LLC purchased a new position in Lexicon Pharmaceuticals during the first quarter worth about $174,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.